We confirmed these results, finding that by day six post-injury, the acetone scores of wildtype mice were 4.160.1 , which remained constant over the following two days . TRPM8-/- mice exhibited a score of 1.660.3 by day six post-injury, which was not significantly different fromthe baseline value of 1.360.1 and did not significantly increase over the next two days . As with the inflammatory model, these data reaffirm the role of TRPM8 in CCI-evoked cold INCB28060 c-Met inhibitor hypersensitivity . Next we tested whether PBMC could reduce cold hypersensitivity in these two pain models. For CFA-induced inflammation, when 10 mg/kg PBMC was injected on the peak response day , we observed a response score of 2.560.2 one hour after drug administration, which was significantly lower than the vehicle WZ8040 control group . The effect of PBMC wore off within 24 hours, when acetone responses scores increased to 3.060.1, values not significantly different from the vehicle control group . Similarly, in the CCI model, when 10 mg/kg PBMC was administered to injured wildtype mice on day seven post-injury, the behavioral response scores dropped to 3.060.1 one hour after the injection, a significant decrease when compared to vehicle-treated animals . As for CFA, this amelioration of cold hypersensitivity was transient with animals returning to the sensitized state 24 hours later . Thus PBMC is effective in diminishing symptoms of cold hypersensitivity in these two models of inflammatory and neuropathic pain. Finally, we tested the effect of PBMC on a systemic neuropathic injury model. The platinum-based chemotherapeutic drug oxaliplatin is known to induce significant cold hypersensitivity which has been attributed to TRPM8 . Animals injected with oxaliplatin developed a heightened response to acetone application that increased from 2.360.2 at baseline to 3.360.1 by day three post-injection and remained constant through day seven post-injury . This increase was absent in TRPM8-/- mice injected with oxaliplatin , thus confirming that the channel is required for oxaliplatin-induced cold hypersensitivity. However, unlike the CFA and CCI models, 10 mg/kg PBMC did not significantly attenuate cold hypersensitivity when administered on day three post�Cinjection, with scores only decreasing to 3.060.1 as compared to 3.360.1 for vehicle-treated animals .